Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849024 | 0.92 | CYP19A1 (0.40) | CYP19A1ARAKR1C3TSHRMAPK1 | |
| SCHEMBL6852215 | 0.87 | CYP19A1 (0.37) | CYP19A1ARAKR1C3TSHRMAPK1 | |
| SCHEMBL6854222 | 0.84 | CYP19A1 (0.40) | CYP19A1AR | |
| SCHEMBL4587874 | 0.82 | CYP19A1 (0.47) | CYP19A1ARAKR1C3TSHRMAPK1 | |
| SCHEMBL8083271 | 0.80 | CYP19A1 (0.42) | CYP19A1AKR1C3CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6912936 | 0.80 | CYP19A1 (0.37) | CYP19A1ARPGR | |
| SCHEMBL9627682 | 0.80 | CYP19A1 (0.55) | CYP19A1ARPGR | |
| SCHEMBL7020267 | 0.80 | CYP19A1 (0.55) | CYP19A1ARPGR | |
| SCHEMBL13804526 | 0.77 | CYP19A1 (0.57) | CYP19A1ARAKR1C3TSHRMAPK1 | |
| SCHEMBL3653263 | 0.77 | CYP19A1 (0.57) | CYP19A1ARAKR1C3TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780855-B2 | TREATING A PATIENT SUFFERING FROM AN ESTROGEN DEPENDENT-DISEASE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-24 | — | — | US | disclosed |
| US-20030069434-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | US | disclosed |
| EP-1042355-B1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069434-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | CYP19A1, HSD17B11, NR5A1 | CYP19A1 1/4885AR 159/4885AKR1C3 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.